Leading diagnostics laboratory in the Caribbean selects Molecular Biology Systems s NextGenPCR for SARS-CoV-2 testing
Share Article
Clinical implementation of ultra-fast molecular testing improves time to result and laboratory throughout
“Throughout, labs have wanted to deliver more by increasing the efficiency of their workflow. - Gert de Vos, MBS CEO and Founder FREDERICK, Md. (PRWEB) April 07, 2021 Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba’s Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing. With a single NextGenPCR system capable of producing over 1,000 results per day, Laboratorio di Servicio has ensured they have capacity beyond their current 300 test results per day.